文献速递免疫规划传染病防控与疫情报告

PAR-2激活肽作为黏膜佐剂增强流感疫苗免疫细胞募集与活化

Mucosal adjuvant activity of a PAR-2-activating peptide enhances lymph node immune cell recruitment and promotes immune cell activation in a prime-boost influenza vaccination model.
PubMed 文献 · Vaccine · 2026-09-04

本研究在小鼠鼻内接种模型中,将蛋白酶激活受体2(PAR-2)激活肽(AP)与流感病毒体佐剂共递送,观察引流淋巴结和肺内免疫变化。结果显示AP促进淋巴细胞和髓系细胞向纵隔淋巴结积聚,增强树突状细胞成熟及CCR7表达,并增加初始、中央记忆和效应记忆T细胞,同时促进肺组织驻留记忆T细胞和单核细胞存在,表明AP作为黏膜佐剂可增强早期免疫细胞募集、DC活化和适应性T细胞应答,促进组织驻留免疫。

要点

  • PAR-2激活肽(AP)与流感病毒体鼻内共递送可增强小鼠黏膜佐剂效应。
  • AP促进纵隔淋巴结免疫细胞积聚、DC成熟及CCR7表达。
  • AP增加淋巴结T细胞亚群并促进肺组织驻留记忆T细胞形成。

核心结论

  • AP作为黏膜佐剂通过增强早期免疫细胞募集、DC活化和淋巴结T细胞应答,促进组织驻留免疫,提示PAR-2激活可改善黏膜流感疫苗效力。

研究设计与样本

  • 小鼠鼻内接种模型,采用PAR-2激活肽(AP)与流感病毒体共递送进行初免-加强免疫,检测引流淋巴结和肺内免疫变化。

主要发现

  • AP促进淋巴系和髓系细胞向纵隔淋巴结积聚,包括CD3+ T细胞和CD11b-/CD11b+树突状细胞(DC)。
  • AP增强DC成熟和CCR7表达,促进其向淋巴结迁移。
  • AP增加淋巴结中初始、中央记忆(TCM)和效应记忆(TEM)T细胞。
  • AP促进肺内组织驻留记忆T细胞(TRM)和单核细胞存在。

临床怎么用

  • 提示PAR-2激活肽可作为黏膜佐剂策略,用于增强鼻内流感疫苗的早期免疫招募和组织驻留免疫。

局限性

  • 研究为小鼠模型,尚未在人体验证;原文未报告具体样本量、效应量及统计学阈值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Influenza A virus (IAV) remains a global health challenge, and current intramuscular vaccines often fail to induce strong mucosal immunity in the airways. We have developed a novel intranasal vaccination strategy in mice using a Protease-Activated Receptor 2 (PAR-2)-activating peptide (AP) as an adjuvant co-delivered with influenza virosomes. We have previously shown that this peptide enhances virosome-induced CD8+ T cell responses and protection against lethal IAV challenge. Here we studied the immune changes induced by this peptide in draining lymph nodes and the lung. We show that AP promotes accumulation of lymphoid and myeloid cells to the mediastinal lymph nodes, including CD3+ T cells and CD11b-/CD11b+ dendritic cells (DCs), and enhances DC maturation and CCR7 expression, which facilitates migration to lymph nodes. Along with accumulation of antigen-presenting cells, we detected increases in naïve, central memory (TCM), and effector memory (TEM) T cells. In addition, AP promoted the presence of tissue-resident memory T cells (TRM) and monocytes in the lungs, supporting rapid tissue-targeted immunity. These results demonstrate that AP functions as a potent mucosal adjuvant by enhancing early immune cell recruitment, DC activation, and adaptive T cell responses in lymph nodes, ultimately promoting tissue-resident immunity. Our findings highlight the potential of PAR-2 activation to improve efficacy of mucosal influenza vaccines.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Kornuta CA, Zhou G, Kane KP, et al. Mucosal adjuvant activity of a PAR-2-activating peptide enhances lymph node immune cell recruitment and promotes immune cell activation in a prime-boost influenza vaccination model. Vaccine. 2026. PMID: 42696827. doi:10.1016/j.vaccine.2026.129110

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。